Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Dan Spillane who wrote (2015)	5/15/1999 5:44:00 PM
From: NAGINDAS J.O.PATTNI	Respond to of 2539

pure unadulterated burocratic franco-german bullshit! nagin

To: Dan Spillane who wrote (2015)	5/16/1999 7:24:00 AM
From: Anthony Wong	Respond to of 2539

Arthritis Foundation urges calm amid drug safety concerns Friday May 14 6:06 PM ET NEW YORK, May 14 (Reuters Health) -- The Arthritis Foundation issued a statement on Friday that urged against ''undue alarm'' regarding alleged safety concerns surrounding two new arthritis drugs, celecoxib (Celebrex) and etanercept (Enbrel). The Atlanta, Georgia-based foundation said that it believes that the Food and Drug Administration's (FDA) drug safety monitoring systems are working ''to ensure the quality and efficacy of medications available to the public.'' The Foundation said that government and manufacturer reviews of deaths of patients taking the drugs indicated that these individuals might have also been taking other medications or had other medical problems that contributed to their deaths. Based on current information ''there is no causal relationship'' between the drugs and the reported deaths, according the statement. The Arthritis Foundation suggests that patients taking arthritis medications consult with their physician about the appropriate medication for them, understand their own personal risk factors, know the warning signs for dangerous reactions, and consult with their physician as soon as problems occur. As reported by Reuters Health last week, Immunex, the manufacturer of Enbrel, warned physicians that the drug has been associated with 30 reports of serious infections, including sepsis, since its approval last November. The FDA said that it would expand the warning label for Enbrel to include a contraindication for patients ''with any active infection, including chronic or localized infections.'' Last month, the FDA said that consumers should not worry about Celebrex amid reports of 10 deaths among patients taking the drug. A spokeswoman for Monsanto, whose GD Searle unit manufactures the drug, said that there was no evidence to suggest a causal relationship between a patient's death or hospitalization due to the use of Celebrex. dailynews.yahoo.com

To: Dan Spillane who wrote (2015)	5/16/1999 7:34:00 AM
From: Anthony Wong	Read Replies (3) \| Respond to of 2539

BMA to Issue Report on Effects of Eating GM Foods, Paper Says Bloomberg News May 16, 1999, 2:32 a.m. PT London, May 16 (Bloomberg) -- The U.K. 's British Medical Association, which represents 115,000 doctors, will issue a report this week saying too little is known about the long-term risks of eating genetically modified foods to guarantee its safety, the Independent on Sunday reported, citing the report. The report, to be published on Tuesday, marks the first official opinion by a British medical body on GM crops and will say detailed research is needed into possible toxicity of GM foods and whether its consumption could lead to new allergies and antibiotic resistance. It will reinforce pressure for a government-backed moratorium on the commercial growing of GM crops in Britain, the paper said. The Wall Street Journal reported May 11 that Monsanto Co.'s genetically altered food has been criticized by U.K. environmental groups and media commentators, and some retailers won't sell the food. (Independent on Sunday 5/16 1 www.independent.co.uk) news.com